Sequencing of chemotherapy and radiation therapy for early breast cancer

Hickey, Brigid E; Francis, Daniel; Lehman, Margot

doi:10.1002/14651858.cd005212.pub2

Cited by 21 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are no definite biomarkers to forecast the metastatic potential of ER -/PR -(13) and triple-negative (ER -/PR -/HER-2 -) breast cancer. Surgery accompanied with radiotherapy, chemotherapy, and biotherapy is the most successful treatment strategy for breast cancer (14,15). However, f40% of patients die of breast cancer recurrence and metastasis.…”

Section: Discussionmentioning

confidence: 99%

Identification of Metastasis-Related Proteins and Their Clinical Relevance to Triple-Negative Human Breast Cancer

Sun

Zhang

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Currently, there are no definite biomarkers of triple-negative breast cancer. The study aims to identify the metastasis-associated proteins of triple-negative breast tumors. Experimental Design: A murine metastatic breast cancer model has been established by using TA2 mice. Parallel proteomic analyses were done on a murine metastatic breast cancer model and its primary breast cancer using two-dimensional gel electrophoresis. The differentially expressed proteins were detected inTA2 mice developing spontaneous breast cancer and lung metastasis. Furthermore, their expression were detected in human breast cancer with or without metastasis, and their prediction values were assessed in a second set of samples. Results: Nineteen of 36 differentially expressed proteins were identified by peptide mass fingerprinting using matrix-assisted laser-desorption ionization-time of flight-mass spectrometry.These proteins were also validated in mouse tumor tissues by immunohistochemical staining. Actin, 14-3-3, vimentin, HSP70, CK18, and moesin were up-regulated in the metastatic tumors, whereas HSP90 and tubulin were absent or down-regulated. Furthermore, 61patients with triple-negative breast cancer and 39 patients with estrogen receptor-positive/progesterone receptor-positive breast cancer were selected for exploring the clinical relevance of these identified proteins to human breast cancer metastasis. Expression of 14-3-3 and HSP70 was significantly correlated with metastasis of human triple-negative breast cancer. Moreover, the validation study in the second set confirmed that 14-3-3, HSP70, and their combination had high sensitivities and specificities in predicting metastatic potential of triple-negative breast cancer. Conclusions:These tumor metastasis-associated proteins validated may be useful as biomarkers and targets for diagnosis and treatment of human triple-negative breast cancer.Breast cancer metastasis is the main cause of treatment failure, exerting a remarkably negative effect on the cure and survival of patients suffering from breast cancer. Metastasis is a multiplestep process involving numerous genes (1, 2). There are two distinct hypotheses regarding tumor metastasis: heterogeneous metastasis and synchronous metastasis. Heterogeneous metastasis is defined as malignant tumor cells spreading to other organs in the late stage (3), whereas synchronous metastasis is described as tumor cells disseminating very early and evolving into metastatic disease independent from the primary tumor (4), suggesting that protein expression in the metastatic tumor may be different from the primary tumor (5). Therefore, the identification of metastasis protein markers in the early stage may contribute to early diagnosis and treatment of breast cancer patients with high risk of metastasis.Triple-negative breast cancer is the subtype of invasive breast cancer with estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative phenotype, an important subtype of breast cancer due to its re...

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Metastasis-Related Proteins and Their Clinical Relevance to Triple-Negative Human Breast Cancer

Sun

Zhang

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Therapy for advanced disease relies largely on chemotherapy and radiation therapy (reviewed in [2-5]), both of which have significant host toxicity and themselves promote mutations, fueling disease progression and treatment resistance.…”

Section: Introductionmentioning

confidence: 99%

Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells

et al. 2007

View full text Add to dashboard Cite

show abstract

“…4 -6,9,10 Other retrospective studies did not confirm this finding 7,8 likely because of a bias effect in the proportion of patients with positive or close surgical margins between radiotherapy-first and radiotherapy-delayed group of patients. 18,19 Data from 3 well conducted randomized trials have been recently analyzed by a Cochrane systematic review, 11 which concluded that local control and survival is similar for concurrent radiotherapy and chemotherapy, radiotherapy followed by chemotherapy, and chemotherapy followed by radiotherapy when radiotherapy is commenced within 7 months after surgery. However, the small statistical power for detecting a clinically important risk difference associated to the low event rate for local recurrence, suggested some cautions in interpreting the results.…”

Section: Discussionmentioning

confidence: 99%

“…However, a recently published Cochrane review from 3 well conducted randomized trials on the sequencing of chemotherapy and radiotherapy suggested that different sequencing of the 2 modalities has no impact on survival or recurrence rates of breast cancer if radiotherapy is commenced within 7 months after surgery. 11 Naturally, the concurrent administration of chemotherapy and radiation would eliminate the need of delaying the initiation of 1 modality until after the end of the other and could provide an additive interaction to tumor response. However, an increase in toxicity and a reduction in patient compliance that may occur after the concomitant treatment, and could prevent adjuvant chemotherapy from being fully and correctly delivered.…”

mentioning

confidence: 99%

Long-Term Results of a Randomized Trial on the Sequencing of Radiotherapy and Chemotherapy in Breast Cancer

Pinnarò¹,

Rambone²,

Giordano³

et al. 2011

American Journal of Clinical Oncology

View full text Add to dashboard Cite

No influence of the treatment sequence on long-term outcomes was observed in this trial. This finding suggests that to avoid an increased risk of distant recurrence or an excessive toxicity, radiation therapy may be delayed until after the end of the more, recently used, anthracycline-based chemotherapy without increasing the risk of breast recurrences, thus allowing the delivery of full-dose chemotherapy in patients at risk for systemic disease spread.

show abstract

Sequencing of chemotherapy and radiation therapy for early breast cancer

Cited by 21 publications

References 50 publications

Identification of Metastasis-Related Proteins and Their Clinical Relevance to Triple-Negative Human Breast Cancer

Identification of Metastasis-Related Proteins and Their Clinical Relevance to Triple-Negative Human Breast Cancer

Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells

Long-Term Results of a Randomized Trial on the Sequencing of Radiotherapy and Chemotherapy in Breast Cancer

Contact Info

Product

Resources

About